Can mesenchymal stem cell therapy be the interim management of COVID-19?
Identifieur interne : 001694 ( Main/Exploration ); précédent : 001693; suivant : 001695Can mesenchymal stem cell therapy be the interim management of COVID-19?
Auteurs : Chitra Bamba [Inde] ; Surinder P. Singh [Inde] ; Sangeeta Choudhury [Inde]Source :
- Drug discoveries & therapeutics [ 1881-784X ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (administration et posologie), Betacoronavirus (MeSH), Cytokines (antagonistes et inhibiteurs), Cytokines (sang), Essais cliniques comme sujet (méthodes), Humains (MeSH), Infections à coronavirus (diagnostic), Infections à coronavirus (sang), Infections à coronavirus (thérapie), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (sang), Pneumopathie virale (thérapie), Prise en charge de la maladie (MeSH), Transplantation de cellules souches mésenchymateuses (méthodes), Transplantation de cellules souches mésenchymateuses (tendances).
- MESH :
- administration et posologie : Antiviraux.
- antagonistes et inhibiteurs : Cytokines.
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- méthodes : Essais cliniques comme sujet, Transplantation de cellules souches mésenchymateuses.
- sang : Cytokines, Infections à coronavirus, Pneumopathie virale.
- tendances : Transplantation de cellules souches mésenchymateuses.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus.
- Betacoronavirus, Humains, Pandémies, Prise en charge de la maladie.
English descriptors
- KwdEn :
- Antiviral Agents (administration & dosage), Betacoronavirus (MeSH), COVID-19 (MeSH), Clinical Trials as Topic (methods), Coronavirus Infections (blood), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (therapy), Cytokines (antagonists & inhibitors), Cytokines (blood), Disease Management (MeSH), Humans (MeSH), Mesenchymal Stem Cell Transplantation (methods), Mesenchymal Stem Cell Transplantation (trends), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (diagnosis), Pneumonia, Viral (therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , administration & dosage : Antiviral Agents.
- chemical , antagonists & inhibitors : Cytokines.
- blood : Coronavirus Infections, Cytokines, Pneumonia, Viral.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections.
- methods : Clinical Trials as Topic, Mesenchymal Stem Cell Transplantation.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- trends : Mesenchymal Stem Cell Transplantation.
- Betacoronavirus, COVID-19, Disease Management, Humans, Pandemics, SARS-CoV-2.
Abstract
COVID-19 pandemic has accounted for ~ 4.3 million confirmed cases and ~ 292,000 deaths (till 12th May, 2020) across the globe since its outbreak. Several anti-viral drugs such as RNA dependent RNA polymerase inhibitors (remdesivir, favipiravir, ribavirin), protease inhibitors (lopinavir, ritonavir) and drugs targeting endocytic pathway (hydroxychloroquine) are being evaluated for COVID-19 but standard therapeutics yet not available. Severe health deterioration in critically ill patients is characterized by pulmonary edema, severe respiratory distress, cytokine storm and septic shock. To combat cytokine storm, immune-therapy targeting IL-1, IL-2, IL-6 and TNFα are being evaluated and one of the promising immune-modulator is the mesenchymal stem cells (MSCs) that can surmount the severity of COVID-19 infections. Recent studies have shown that MSC-therapy significantly dampens the cytokine storm in critically ill COVID-19 patients. This communication endows with the insight of stem cell therapy and summarizes the recent studies on COVID-19 patients.
DOI: 10.5582/ddt.2020.03032
PubMed: 32554953
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Can mesenchymal stem cell therapy be the interim management of COVID-19?</title><author><name sortKey="Bamba, Chitra" sort="Bamba, Chitra" uniqKey="Bamba C" first="Chitra" last="Bamba">Chitra Bamba</name><affiliation wicri:level="1"><nlm:affiliation>Department of Research, Sir Ganga Ram Hospital, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Research, Sir Ganga Ram Hospital, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Singh, Surinder P" sort="Singh, Surinder P" uniqKey="Singh S" first="Surinder P" last="Singh">Surinder P. Singh</name><affiliation wicri:level="1"><nlm:affiliation>CSIR-National Physical Laboratory, Dr K. S. Krishnan Marg, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>CSIR-National Physical Laboratory, Dr K. S. Krishnan Marg, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Choudhury, Sangeeta" sort="Choudhury, Sangeeta" uniqKey="Choudhury S" first="Sangeeta" last="Choudhury">Sangeeta Choudhury</name><affiliation wicri:level="1"><nlm:affiliation>Department of Research, Sir Ganga Ram Hospital, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Research, Sir Ganga Ram Hospital, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32554953</idno><idno type="pmid">32554953</idno><idno type="doi">10.5582/ddt.2020.03032</idno><idno type="wicri:Area/Main/Corpus">001380</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001380</idno><idno type="wicri:Area/Main/Curation">001380</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001380</idno><idno type="wicri:Area/Main/Exploration">001380</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Can mesenchymal stem cell therapy be the interim management of COVID-19?</title><author><name sortKey="Bamba, Chitra" sort="Bamba, Chitra" uniqKey="Bamba C" first="Chitra" last="Bamba">Chitra Bamba</name><affiliation wicri:level="1"><nlm:affiliation>Department of Research, Sir Ganga Ram Hospital, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Research, Sir Ganga Ram Hospital, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Singh, Surinder P" sort="Singh, Surinder P" uniqKey="Singh S" first="Surinder P" last="Singh">Surinder P. Singh</name><affiliation wicri:level="1"><nlm:affiliation>CSIR-National Physical Laboratory, Dr K. S. Krishnan Marg, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>CSIR-National Physical Laboratory, Dr K. S. Krishnan Marg, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Choudhury, Sangeeta" sort="Choudhury, Sangeeta" uniqKey="Choudhury S" first="Sangeeta" last="Choudhury">Sangeeta Choudhury</name><affiliation wicri:level="1"><nlm:affiliation>Department of Research, Sir Ganga Ram Hospital, New Delhi, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Research, Sir Ganga Ram Hospital, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author></analytic><series><title level="j">Drug discoveries & therapeutics</title><idno type="eISSN">1881-784X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Clinical Trials as Topic (methods)</term><term>Coronavirus Infections (blood)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (therapy)</term><term>Cytokines (antagonists & inhibitors)</term><term>Cytokines (blood)</term><term>Disease Management (MeSH)</term><term>Humans (MeSH)</term><term>Mesenchymal Stem Cell Transplantation (methods)</term><term>Mesenchymal Stem Cell Transplantation (trends)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (blood)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (therapy)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (administration et posologie)</term><term>Betacoronavirus (MeSH)</term><term>Cytokines (antagonistes et inhibiteurs)</term><term>Cytokines (sang)</term><term>Essais cliniques comme sujet (méthodes)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (sang)</term><term>Infections à coronavirus (thérapie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (sang)</term><term>Pneumopathie virale (thérapie)</term><term>Prise en charge de la maladie (MeSH)</term><term>Transplantation de cellules souches mésenchymateuses (méthodes)</term><term>Transplantation de cellules souches mésenchymateuses (tendances)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term><term>Cytokines</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term><term>Mesenchymal Stem Cell Transplantation</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Essais cliniques comme sujet</term><term>Transplantation de cellules souches mésenchymateuses</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Cytokines</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Transplantation de cellules souches mésenchymateuses</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Mesenchymal Stem Cell Transplantation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Disease Management</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Humains</term><term>Pandémies</term><term>Prise en charge de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">COVID-19 pandemic has accounted for ~ 4.3 million confirmed cases and ~ 292,000 deaths (till 12<sup>th</sup> May, 2020) across the globe since its outbreak. Several anti-viral drugs such as RNA dependent RNA polymerase inhibitors (remdesivir, favipiravir, ribavirin), protease inhibitors (lopinavir, ritonavir) and drugs targeting endocytic pathway (hydroxychloroquine) are being evaluated for COVID-19 but standard therapeutics yet not available. Severe health deterioration in critically ill patients is characterized by pulmonary edema, severe respiratory distress, cytokine storm and septic shock. To combat cytokine storm, immune-therapy targeting IL-1, IL-2, IL-6 and TNFα are being evaluated and one of the promising immune-modulator is the mesenchymal stem cells (MSCs) that can surmount the severity of COVID-19 infections. Recent studies have shown that MSC-therapy significantly dampens the cytokine storm in critically ill COVID-19 patients. This communication endows with the insight of stem cell therapy and summarizes the recent studies on COVID-19 patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32554953</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1881-784X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Drug discoveries & therapeutics</Title><ISOAbbreviation>Drug Discov Ther</ISOAbbreviation></Journal><ArticleTitle>Can mesenchymal stem cell therapy be the interim management of COVID-19?</ArticleTitle><Pagination><MedlinePgn>139-142</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5582/ddt.2020.03032</ELocationID><Abstract><AbstractText>COVID-19 pandemic has accounted for ~ 4.3 million confirmed cases and ~ 292,000 deaths (till 12<sup>th</sup> May, 2020) across the globe since its outbreak. Several anti-viral drugs such as RNA dependent RNA polymerase inhibitors (remdesivir, favipiravir, ribavirin), protease inhibitors (lopinavir, ritonavir) and drugs targeting endocytic pathway (hydroxychloroquine) are being evaluated for COVID-19 but standard therapeutics yet not available. Severe health deterioration in critically ill patients is characterized by pulmonary edema, severe respiratory distress, cytokine storm and septic shock. To combat cytokine storm, immune-therapy targeting IL-1, IL-2, IL-6 and TNFα are being evaluated and one of the promising immune-modulator is the mesenchymal stem cells (MSCs) that can surmount the severity of COVID-19 infections. Recent studies have shown that MSC-therapy significantly dampens the cytokine storm in critically ill COVID-19 patients. This communication endows with the insight of stem cell therapy and summarizes the recent studies on COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bamba</LastName><ForeName>Chitra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Research, Sir Ganga Ram Hospital, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Surinder P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>CSIR-National Physical Laboratory, Dr K. S. Krishnan Marg, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhury</LastName><ForeName>Sangeeta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Research, Sir Ganga Ram Hospital, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Drug Discov Ther</MedlineTA><NlmUniqueID>101493809</NlmUniqueID><ISSNLinking>1881-7831</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="N">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MSC-therapy</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">novel coronavirus disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32554953</ArticleId><ArticleId IdType="doi">10.5582/ddt.2020.03032</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Bamba, Chitra" sort="Bamba, Chitra" uniqKey="Bamba C" first="Chitra" last="Bamba">Chitra Bamba</name></noRegion><name sortKey="Choudhury, Sangeeta" sort="Choudhury, Sangeeta" uniqKey="Choudhury S" first="Sangeeta" last="Choudhury">Sangeeta Choudhury</name><name sortKey="Singh, Surinder P" sort="Singh, Surinder P" uniqKey="Singh S" first="Surinder P" last="Singh">Surinder P. Singh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001694 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001694 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32554953
|texte= Can mesenchymal stem cell therapy be the interim management of COVID-19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32554953" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |